



CONTRA
 COSTA
 HEALTH PLAN
 595 Center
 Avenue
 Suite 100
 Martinez, CA
 94553
 925.313.6000
 Date: June 2021

**Contra Costa Health Plan Pharmacy and Therapeutics
 Committee (P&T)**

The CCHP P&T committee met on 6/11/2021. Updates from the meeting are outlined below:

****Changes to the PDL will be effective by mid-July 2021****

Updates/Announcements:

1. Fee-For-Service Medi-Cal Carve-Out (Medi-Cal Rx) has been delayed indefinitely:

The Department of Health Care Services (DHCS) is delaying the planned Go-Live date of April 1, 2021, for Medi-Cal Rx because of the need to review new conflict avoidance protocols submitted by Magellan Health, Inc. (Magellan), the project's contracted vendor. While DHCS has indicated that an update for Medi-Cal Rx would come in May 2021, there has not yet been an update announced. CCHP is watching for an update and will take the appropriate action when an update is announced.

Quick reference table for all changes to the Preferred Drug List (PDL) and/or Prior Authorization (PA) criteria (for full details of each change, please see individual drugs listed below this table):

<u>Changes Made</u>	<u>Drug Name</u>
Created new PA criteria:	Testosterone products: Androderm 2 mg and 4 mg patches, Androgel 1% 2.5 gm and 5 gm packets, Vogelxo 1% topical gel in pump Orilissa (elagolix) 150 mg and 200 mg tablets Qelbree (viloxazine)
Modified PA criteria:	Freestyle Libre Readers and Sensors Humira (adalimumab) Anti-Obesity Medications: Xenical (orlistat) and Qsymia (phentermine/topiramate)

	<p>Epidiolex (cannabidiol)</p> <p>CGRP antagonists: Aimovig, Emgality, Vyepti</p> <p>Enbrel (etanercept)</p> <p>Simponi (golimumab)</p> <p>Infliximab</p> <p>Xeljanz XR (tofacitinib)</p> <p>Stelara (ustekinumab)</p> <p>Entyvio (vedolizumab)</p>
ADDED to the CCHP formulary:	Cabenuva (cabotegravir/rilpivirine) 400 mg/600 mg
Removed from CCHP formulary:	<p>Pentobarbital sodium 50 mg/mL injection solution</p> <p>Phenobarbital sodium 65 mg/mL and 130 mg/mL injection solution</p> <p>Fosphenytoin 100 mg/2 mL and 500 mg/10 mL injection solution</p> <p>Levetiracetam 500 mg/5 mL IV solution</p> <p>Valproate sodium 500 mg/5 mL IV solution</p> <p>Diazepam 5 mg/mL injection solution/syringe</p>

- **Newly Established criteria for Testosterone products**: For Androdel 1% packets and Vogelxo 1% gel, requires a trial and failure or found to be intolerant to the first line preferred agents, testosterone cypionate injection or testosterone enanthate injection. For Androderm patches, requires trial and failure of a first line agent and a second line agent.
- **Newly Established criteria for Orlistat (orlistat)**: requires a trial and failure to at least 2 NSAIDs and at least one hormonal medication
- **Newly Established criteria for Qelbree (viloxazine)**: requires a trial and failure to at least 2 formulary stimulant medications and a trial and failure of Straterra (atomoxetine)
- **Modification of criteria for Freestyle Libre Readers and Sensors**: change criteria to 4 or more tests per day and added an option for approval if member has clinically significant episode of hypoglycemia resulting in acute care or a pattern of hypoglycemia
- **Modification of criteria for Humira (adalimumab)**: added indication for polyarticular juvenile idiopathic arthritis. Separated Ulcerative Colitis and Crohn's disease criteria into separate criterias

- **Modification of criteria for Anti-Obesity Medications** : added Xenical criteria (try and fail Alli) and added Qsymia (phentermine/topiramate) criteria of trial and failure of as separate medications
- **Modification of criteria for Epidiolex (cannabidiol)** : added criteria for tuberous sclerosis complex
- **Modification of criteria for CGRP antagonists (Aimovig, Emgality, Vyepti)** : updated criteria to include documentation of number of headache days per month
- **Modification of criteria for Enbrel (etanercept)** : added indication for polyarticular juvenile idiopathic arthritis
- **Modification of criteria for Simponi (golimumab)** : added indication for polyarticular juvenile idiopathic arthritis
- **Modification of criteria for infliximab** : separated Ulcerative Colitis and Crohn's disease criteria into separate criterias
- **Modification of criteria for Xeljanz (tofacitnib)** : added indication for polyarticular juvenile idiopathic arthritis
- **Modification of criteria for Stelara (ustekinumab)** : separated Ulcerative Colitis and Crohn's disease criteria into separate criterias
- **Modification of criteria for Entyvio (vedolizumab)** : separated Ulcerative Colitis and Crohn's disease criteria into separate criterias

There are numerous ways to view the CCHP Preferred Drug List:

CCHP updates the Preferred Drug List (PDL) after each quarterly Pharmacy & Therapeutics Committee meeting. CCHP invites and encourages practitioners to access each update through the following means:

- An interactive searchable formulary is available within Epic (contact the Epic team with any questions related to functionality).
- A printable copy of the CCHP PDL can be found here: <http://cchealth.org/healthplan/pdf/pdl.pdf>
- A searchable copy of the CCHP PDL can be found here: <http://formularynavigator.com/Search.aspx?siteID=MMRREQ3QBC>
- **EPOCRATES – free mobile & online formulary resource**
 - CCHP providers may add the CCHP formulary to their mobile devices using the following steps:
 - Open the Epocrates application on your mobile device.
 - Click on the “formulary” button on the home screen.
 - Click “add new formulary” button on the bottom of the screen.

▪ Use the search box to locate “Contra Costa Health Plan” Medi-Cal or Commercial formulary. Click on each formulary that you would like to add, and then click the “add formulary” button.

Epocrates mobile is supported on the iOS (iPhone, iTouch, iPad), Android, & BlackBerry platforms

If you have any questions about the installation or use of Epocrates, please contact Epocrates Customer Support at goldsupport@epocrates.com or at (800)230-2150.

Providers may request a copy of CCHP pharmacy management procedures or specific drug PA criteria by contacting the pharmacy unit directly at 925-957-7260 x1, or via the email listed below:

P&T updates and DUR educational bulletins can be viewed online at <http://cchealth.org/healthplan/provider-pharmacy-therapeutics.php>

Questions and comments may be directed to CCHP Pharmacy by emailing joseph.cardinalli@cchealth.org
